Abstract
Data are limited on the safety and efficacy of direct oral anticoagulants (DOACs) in obese patients (BMI > 30 kg/m2) with atrial fibrillation (AF). We analyzed a cohort of obese patients from the Veterans Administration (VA) health system with AF who initiated apixaban (APIX), rivaroxaban (RIVA),
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
